Yazılar

Nvidia unveils AI models for faster, cheaper weather forecasts

/in /tarafından

Nvidia has released three open-source artificial intelligence models designed to improve the speed and cost efficiency of weather forecasting. The announcement was made at the American Meteorological Society’s annual meeting, highlighting the chipmaker’s broader push to apply AI software beyond traditional computing workloads.

The new models aim to replace conventional weather simulations, which are often expensive and time-consuming to run. Nvidia said its AI-driven approach can match or exceed the accuracy of traditional methods while delivering results significantly faster and at a lower operational cost once the models are trained.

One of the key commercial use cases is expected to be in the insurance sector, where companies rely on large-scale weather simulations to assess rare but damaging events such as floods and hurricanes. Traditional forecasting requires running large ensembles of simulations, a process that can be slow and costly. Nvidia said AI removes this bottleneck by enabling massive ensembles to be processed at unprecedented speed.

The models are part of Nvidia’s Earth-2 initiative and include tools for 15-day global forecasts, short-term severe storm prediction over the United States, and systems that combine data from multiple weather sensors to improve forecasting accuracy.

Drugmakers Turn to AI to Speed Trials and Submissions

/in /tarafından

Pharmaceutical companies are increasingly using artificial intelligence to accelerate clinical trials and regulatory submissions, even as AI has yet to deliver major breakthroughs in discovering new drugs. Industry executives say the technology is already saving weeks by automating participant recruitment, site selection, and the preparation of vast regulatory documentation.

Executives from major drugmakers including Eli Lilly, AstraZeneca, Roche, and Pfizer said at the JP Morgan Healthcare Conference that AI tools are helping manage thousands of pages of clinical, safety, and manufacturing records required by regulators worldwide.

Drug development can take more than a decade and cost around $2 billion. Companies are betting that AI can improve efficiency and success rates by handling what executives call the “messy middle” of development. Consultancy McKinsey estimates that autonomous, or agentic, AI could lift clinical development productivity by up to 45% over the next five years.

Israeli drugmaker Teva Pharmaceutical Industries said it is using AI to streamline processes so researchers can focus on bringing new medicines to market. Meanwhile, Novartis used AI to cut site selection for a large cardiovascular trial from weeks to hours, helping it hit enrollment targets with minimal overshoot.

Other companies are also reporting tangible savings. GSK said digital and AI tools helped reduce late-stage trial costs by millions of pounds, while Denmark’s Genmab plans to deploy AI agents to automate post-trial analysis and reporting.

While investors are still waiting for the first fully AI-designed blockbuster drug, executives say the technology is already reshaping how trials are run and how data is submitted. Amgen’s research chief said many AI-designed molecules are already moving through pipelines, suggesting the biggest impact may still lie ahead.

Infosys Shares Jump on Strong FY2026 Outlook, Lifting IT Stocks

/in /tarafından

Shares of Infosys rose about 5% on Friday after the company unexpectedly raised its fiscal 2026 revenue forecast, boosting sentiment across India’s IT sector.

Infosys now expects revenue growth of 3%–3.5% in the year ending March 2026, up from its earlier 2%–3% outlook. The stock led gains on the Nifty 50, while the Nifty IT climbed 2.2%.

Analysts said AI-led partnerships and vendor consolidation are strengthening Infosys’s competitive position. The company has won AI-driven deals with Adobe and Siemens AG, and its large-deal order book rose to a two-year high of $4.8 billion.

At least three brokerages, including Jefferies, raised target prices after the results. The upbeat outlook follows comments from Tata Consultancy Services earlier this week pointing to solid demand in 2026, helping lift broader IT stocks, including Wipro.